BMC Cancer 2008, 8:84 http://www.biomedcentral.com/1471-2407/8/84 gesterone acetate and prednisone in advanced breast can- cer. A randomized trial. Eur J Cancer Clin Oncol 1986, 22(9):1067-1072. 39. Popiela T, Lucchi R, Giongo F: Methylprednisolone as palliative therapy for female terminal cancer patients. The Methyl- prednisolone Female Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 1989, 25(12):1823-1829. 40. Tashiro H, Nomura Y: Mitomycin C, methotrexate, and vincris- tine with medroxyprogesterone acetate or prednisolone for doxorubicin resistant advanced breast cancer--a rand- omized control study. Anticancer Res 1995, 15(5B):2229-2237. 41. Wolf J, Spear P, Yesner R, Patno ME: Nitrogen mustard and the steroid hormones in the treatment of inoperable broncho- genic carcinoma. Am J Med 1960, 29:1008-1016. 42. Wolf J, Spear P, Yesner R, Patno ME: The Sex Hormones and Cortisone in the Treatment of Inoperable Bronchogenic Carcinoma. In Biological activities of steroids in relation to cancer Edited by: Pincus G, Vollmer EP. New York: Academic Press; 1960:413-426. 43. Sander S, Nissen-Meyer R, Aakvaag A: Orchiectomy combined with cyproterone acetate or prednisone in the treatment of advanced prostatic carcinoma. A randomized clinical and endocrine study. Scand J Urol Nephrol 1982, 16(3):193-197. 44. Meakin JW, Hayward JL, Panzarella T, Allt WE, Beale FA, Bulbrook RD, Bush RS, Clark RM, Fitzpatrick PJ, Hawkins NV, et al.: Ovarian irradiation and prednisone following surgery and radiother- apy for carcinoma of the breast. Breast Cancer Res Treat 1996, 37(1):11-19. 45. Rinehart JJ, Davidson S, Deshazo M, Cloud M, Busby L, Robert F: Phase l Trial of Dexamethasone (Dex), Carboplatin (C) and Gemcitabine (G) in Untreated Non-Small Cell Lung Cancer (NSCLC). Proceedings of ASCO 2005, 23(16S):7111. 46. Rubens RD, Tinson CL, Coleman RE, Knight RK, Tong D, Winter PJ, North WR: Prednisolone improves the response to primary endocrine treatment for advanced breast cancer. Br J Cancer 1988, 58(5):626-630. 47. Kristensen B, Ejlertsen B, Holmegaard SN, Krarup-Hansen A, Trans- bol I, Mouridsen H: Prednisolone in the treatment of severe malignant hypercalcaemia in metastatic breast cancer: a randomized study. J Intern Med 1992, 232(3):237-245. 48. Tormey D, Gelman R, Falkson G: Prospective evaluation of rotating chemotherapy in advanced breast cancer. An East- ern Cooperative Oncology Group Trial. Am J Clin Oncol 1983, 6(1):1-18. 49. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, Rowland KM Jr, Camoriano JK, Novotny PJ, Christensen BJ: Ran- domized comparison of megestrol acetate versus dexame- thasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999, 17(10):3299-3306. 50. Tombal B, Tourani J-M, Kizazi K, Culine S, Lotz J-P, Kaci M, Coppola F, Kahatt C, Weems G, Cvitkovic E: Randomized phase ll trial of irofulven (IROF) with or without prednisone in hormone - refractory prostate cancer (HRPC) patients (pts). Proceedings of ASCO 2003, 22:1636. 51. Sato N, Koeda K, Ikeda K, Kimura Y, Aoki K, Iwaya T, Akiyama Y, Ish- ida K, Saito K, Endo S: Randomized study of the benefits of pre- operative corticosteroid administration on the postoperative morbidity and cytokine response in patients undergoing surgery for esophageal cancer. Ann Surg 2002, 236(2):184-190. 52. Bernhardt B, Nemunaitis JJ, Ebrahimi B, Cervera A, Birch R, Richards DA, Smith GB, Allerton JP, Henderson IC: The addition of pred- nisone (Pr) to the combination of docetaxel (T) and perifo- sine (P) decreases the severity of gastrointestinal (GI) toxicity. Proceedings of ASCO 2006, 24(18S):13142. 53. Marini G, Murray S, Goldhirsch A, Gelber RD, Castiglione-Gertsch M, Price KN, Tattersall MH, Rudenstam CM, Collins J, Lindtner J, et al.: The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group. Ann Oncol 1996, 7(3):245-250. 54. Oncologic Drugs Advisory Committee, Fifty-Third Meeting, Center for Drug Evaluation and Research, Food and Drug Administration Bethesda, MD 1997:1-192 [http://www.fda.gov/ohrms/dockets/ac/97/transcpt/ 3289t2.pdf]. 55. Mercer PM, Ebbs SR, Fraser SC, Coltart RS, Bates T: Trial of aminoglutethimide vs hydrocortisone as second-line hor- mone treatment of advanced breast cancer. Eur J Surg Oncol 1993, 19(3):254-258. 56. Wander HE, Kleeberg UR, Essers U, Blossey HC, Nagel GA: Aminoglutethimide plus high-dose medroxyprogesterone acetate versus aminoglutethimide plus cortisone in therapy of metastasizing breast cancer. An AIO phase III study. Onkologie 1987, 10(5):321-323. 57. Graham PH, Capp A, Delaney G, Goozee G, Hickey B, Turner S, Browne L, Milross C, Wirth A: A pilot randomised comparison of dexamethasone 96 mg vs 16 mg per day for malignant spi- nal-cord compression treated by radiotherapy: TROG 01.05 Superdex study. Clin Oncol (R Coll Radiol) 2006, 18(1):70-76. 58. Yano M, Taniguchi M, Tsujinaka T, Fujiwara Y, Yasuda T, Shiozaki H, Monden M: Is preoperative methylprednisolone beneficial for patients undergoing esophagectomy? Hepatogastroenterology 2005, 52(62):481-485. 59. Williams G, Asopa R, Abel PD, Smith C: Pituitary adrenal and gonadal endocrine suppression for the primary treatment of prostate cancer. Br J Urol 1990, 65(5):504-508. 60. Tyrrell C: Liazal Versus Cyproterone Acetate (CPA) or Pred- nisone in Hormone-Resistant Prostate Cancer: Results of Two Clinical Trials. Annals of Oncology 1996, 7(Supplement 5):57. 61. Mercadante SL, Berchovich M, Casuccio A, Fulfaro F, Mangione S: A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. Am J Hosp Palliat Care 2007, 24(1):13-19. 62. Feuer DJ, Broadley KE: Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers. Systematic Review Steering Committee. Ann Oncol 1999, 10(9):1035-1041. 63. Mass RE: Clinical Evaluation Of Oxylone (NSC-33001). Cancer Chemother Rep 1964, 38:49-60. 64. Moertel CG, Reitemeier RJ, Hahn RG, Blackburn CM: Fluorometh- olone (NSC-33001) As A Palliative In Advanced Gastrointes- tinal Carcinoma. Cancer Chemother Rep 1964, 43:25-27. 65. Johnson R, Bisel H, Andrews N, Wilson W, Rochlin D, Segaloff A, Krementz E, Aust J, Ansfield F: Phase l Clinical Study of 6α-Meth- ylpregn-4-ene-3,11,20-trione (NSC-17256). Cancer Chemother Rep 1966, 50(9):671-673. 66. Ramirez G, Weiss AJ, Rochlin DB, Bisel HF: Phase II study of 6 - methylpregn-4-ene-3,11,20-trione (NSC-17256). Cancer Chemother Rep 1971, 55(3):265-268. 67. Bruera E, Roca E, Cedaro L, Carraro S, Chacon R: Action of oral methylprednisolone in terminal cancer patients: a prospec- tive randomized double-blind study. Cancer Treat Rep 1985, 69(7–8):751-754. 68. Postlethwait RW, Moseley V, McKee KT, Murdoch JH Jr, McCord WM: ACTH and cortisone in advanced carcinoma of the digestive tract. Cancer 1951, 4(5):984-987. 69. De Camp G: Corticosteroid therapy in bronchial carcinoma and other malignant tumors in the thorax. Munch Med Wochenschr 1961, 103:2026-2030. 70. Plengvanit U, Viranuvatti V: Treatment Of Primary Carcinoma Of The Liver With Nitrogen Mustard And Prednisolone: Report Of 51 Cases. Am J Gastroenterol 1964, 42:521-528. 71. Rinehart JJ: Randomized Phase ll Trial of Doxil With or With- out Dexamethasone for Metastatic Hormone Refractory Prostate Cancer. ClinicalTrials.gov . [http://clinicaltrials.gov/ show/NCT00176293]. 72. Mouridsen H: Phase ll Randomized Second-Line Endocrine Therapy with AG/HC vs AG vs Low-Dose AG vs Low-Dose AG/HC in Patients with Advanced Breast Cancer EORTC- 10861. . 73. CellGenesys : Docetaxel in Combination with GVAX Vaccine Versus Docetaxel and Prednisone in Prostate Cancer Patients. ClinicalTrials.gov . [http://clinicaltrials.gov/show/ NCT00133224]. 74. Habib GS, Saliba WR: Tumor lysis syndrome after hydrocorti- sone treatment in metastatic melanoma: a case report and review of the literature. Am J Med Sci 2002, 323(3):155-157. 75. Chaudhuri PK, Das Gupta TK, Beattie CW, Walker MJ: Glucocorti- coid-induced exacerbation of metastatic human melanoma. J Surg Oncol 1982, 20(1):49-52. Page 18 of 19 (page number not for citation purposes)